U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H10N2O8S
Molecular Weight 342.283
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RANELIC ACID

SMILES

C(c1c(C#N)c(N(CC(=O)O)CC(=O)O)sc1C(=O)O)C(=O)O

InChI

InChIKey=DJSXNILVACEBLP-UHFFFAOYSA-N
InChI=1S/C12H10N2O8S/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22)

HIDE SMILES / InChI

Molecular Formula C12H10N2O8S
Molecular Weight 342.283
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ranelic acid is an organic acid capable of chelating metal cations. Ranelic acid is an organic, highly polar molecule without pharmacological activity, its salt form, s, is a drug used to treat osteoporosis and increase bone mineral density

Approval Year

PubMed

PubMed

TitleDatePubMed
Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis).
2001 Aug
Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial.
2002 Dec
A review of anabolic therapies for osteoporosis.
2003
Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate.
2003
Is the calcium receptor a molecular target for the actions of strontium on bone?
2003
[Prevention of hip fractures in the elderly: where are we in 2003?].
2003 Apr
Strontium and osteoporosis.
2003 Mar
Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells.
2004 Apr
[New medication combines osteo-anabolic and anti-resorptive effects. Double strategy against osteoporosis].
2004 Apr 1
Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats.
2004 Dec
[Treatment of postmenopausal osteoporosis].
2004 Dec 15
Noninvasive measurement of bone strontium.
2004 Fall
[Preclinical evaluation of strontium ranelate in bone quality].
2004 Feb
Strontium ranelate--a novel therapy for osteoporosis or a permutation of the same?
2004 Jan 29
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
2004 Jan 29
Strontium ranelate: a new paradigm in the treatment of osteoporosis.
2004 Jul
Bone anabolic agents: the unanswered queries.
2004 Jun
Strontium strengthens some bones.
2004 Mar
[Effects of different treatments for osteoporosis on prevention of fractures: toward and individualized and economic approach].
2004 Mar 10
7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture.
2004 Mar 15
[Alternatives to hormone replacement therapy for menopause: an epidemiological evaluation].
2004 May
Postmenopausal osteoporosis and strontium ranelate.
2004 May 6
Postmenopausal osteoporosis and strontium ranelate.
2004 May 6
[Treatment of postmenopausal osteoporosis in 2004].
2004 Nov
Guidelines for the management of postmenopausal osteoporosis for GPs.
2004 Nov
The biological role of strontium.
2004 Sep
Strontium ranelate (Fujisawa/Servier).
2005 Apr
Osteoporosis.
2005 Aug
On some osteoporosis analyses.
2005 Aug
Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.
2005 Feb
[Strontium Ranelate as a new therapeutic agent for osteoporosis].
2005 Jan
Strontium ranelate: a novel mode of action optimizing bone formation and resorption.
2005 Jan
Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.
2005 Jan
Strontium ranelate: a novel mode of action leading to renewed bone quality.
2005 Jan
[Osteoporosis].
2005 Jan 5
[Partnership between academic research and industry to study a new anti-osteoporotic drug].
2005 Jun-Jul
Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action.
2005 Mar
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
2005 May
Long-term effect of strontium ranelate treatment on BMD.
2005 Nov
Cross-cultural validation and analysis of responsiveness of the QUALIOST: QUAlity of Life questionnaire In OSTeoporosis.
2005 Nov 10
Review of treatment modalities for postmenopausal osteoporosis.
2005 Oct
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
2005 Oct
The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options.
2006
Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
2006 Feb
Anabolic agents: a new chapter in the management of osteoporosis.
2006 Feb
Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
2006 Feb
Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment.
2006 Jul
Strontium ranelate--data on vertebral and nonvertebral fracture efficacy and safety: mechanism of action.
2006 Mar
Gynaecological oncology perspective on management of the menopause.
2006 Oct
Patents
Substance Class Chemical
Created
by admin
on Sat Jun 26 14:15:09 UTC 2021
Edited
by admin
on Sat Jun 26 14:15:09 UTC 2021
Record UNII
K9CCS0RIBT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RANELIC ACID
INN   MI   WHO-DD  
INN  
Official Name English
RANELIC ACID [INN]
Common Name English
RANELIC ACID [MI]
Common Name English
RANELIC ACID [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C62357
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL2107175
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
PRIMARY
PUBCHEM
3052774
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
PRIMARY
EVMPD
SUB10255MIG
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
PRIMARY
WIKIPEDIA
RANELIC ACID
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
PRIMARY
INN
7290
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
PRIMARY
CAS
135459-90-4
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
PRIMARY
FDA UNII
K9CCS0RIBT
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
PRIMARY
MERCK INDEX
M9494
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C76602
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
PRIMARY
EPA CompTox
135459-90-4
Created by admin on Sat Jun 26 14:15:09 UTC 2021 , Edited by admin on Sat Jun 26 14:15:09 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY